Giuseppe Viglietto

Catanzaro, 88100, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 100 publications

Expanding the Mutational Spectrum of ACADVL: Integrative Characterization of the p.Ser72Phe Variant in Very Long-Chain Acyl-CoA Dehydrogenase Deficiency.

Expanding the Mutational Spectrum of ACADVL: Integrative Characterization of the p.Ser72Phe Variant in Very Long-Chain Acyl-CoA Dehydrogenase Deficiency.

Journal: Genes

Published: May 07, 2026

Genomic Predictors of Platinum Resistance and Survival in High-Grade Serous Ovarian Carcinoma: Insights from an Explorative Targeted Next-Generation Sequencing Analysis.

Genomic Predictors of Platinum Resistance and Survival in High-Grade Serous Ovarian Carcinoma: Insights from an Explorative Targeted Next-Generation Sequencing Analysis.

Journal: Cancers

Published: March 02, 2026

From laboratory bench to surgical room: Molecular profiling and single-cell technologies in precision surgery for colorectal cancer patients.

From laboratory bench to surgical room: Molecular profiling and single-cell technologies in precision surgery for colorectal cancer patients.

Journal: Surgical oncology

Published: December 29, 2025

Th17/treg balance in Inflammatory Bowel Disease: the role of microbial, and genetic regulators in disease modulation.

Th17/treg balance in Inflammatory Bowel Disease: the role of microbial, and genetic regulators in disease modulation.

Journal: Frontiers in cell and developmental biology

Published: December 24, 2025

Inhibition of the oncogenic GTPase dynamin-related protein 1 (DRP1) by the FDA-approved drug fosaprepitant: In silico, biophysical, and in vitro characterization of its anti-myeloma activity.

Inhibition of the oncogenic GTPase dynamin-related protein 1 (DRP1) by the FDA-approved drug fosaprepitant: In silico, biophysical, and in vitro characterization of its anti-myeloma activity.

Journal: International journal of biological macromolecules

Published: November 18, 2025

Correction: Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclax.

Correction: Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclax.

Journal: Journal of translational medicine

Published: November 11, 2025

The Non-Coding RNA Journal Club: Highlights on Recent Papers-14.

The Non-Coding RNA Journal Club: Highlights on Recent Papers-14.

Journal: Non-coding RNA

Published: September 02, 2025

Hereditary Transthyretin Amyloidosis: Genetic Characterization of the TTR P.Val142Ile Variant in a Calabrian Kindred.

Hereditary Transthyretin Amyloidosis: Genetic Characterization of the TTR P.Val142Ile Variant in a Calabrian Kindred.

Journal: Genes

Published: July 08, 2025

Identification of novel variants underlying non-syndromic primary ovarian insufficiency using a targeted NGS gene panel.

Identification of novel variants underlying non-syndromic primary ovarian insufficiency using a targeted NGS gene panel.

Journal: Frontiers in endocrinology

Published: July 04, 2025

Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclax.

Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclax.

Journal: Journal of translational medicine

Published: July 01, 2025

Cytogenetic and molecular characterization of an atypical ETP-ALL case with BCL2 dependency: therapeutic implications for Venetoclax use.

Cytogenetic and molecular characterization of an atypical ETP-ALL case with BCL2 dependency: therapeutic implications for Venetoclax use.

Journal: Molecular biology reports

Published: June 26, 2025

DRP1-mediated mitochondrial fragmentation is a druggable vulnerability in multiple myeloma.

DRP1-mediated mitochondrial fragmentation is a druggable vulnerability in multiple myeloma.

Journal: Blood

Published: June 11, 2025

Showing 1-12 of 100

Last Updated: 09/26/2026